Teva Pharmaceuticals USA has gained FDA approval to market Xeloda, a generic version of the oral chemotherapy pill used to treat metaticized colorectal cancer and breast cancers. The pills will be available in 150 and 500 milligram strengths.
“Generic drugs are important options that allow greater access to health care for all Americans,” said Kathleen Uhl, M.D., acting director of the Office of Generic Drugs in the Food and Drug Administration’s Center for Drug Evaluation and Research. “This medication is widely used by people living with cancer, so it is important to have access to affordable treatment options.”
According to the National Cancer Institute, approximately 143,000 people will be diagnosed with cancer of the colon and rectum by the end of the year, resulting in 50,830 fatalities. It is also estimated that nearly 232,340 women will be diagnosed with breast cancer, with 39,620 dying from the disease in 2013 alone.
The most common side effects associated with Xeloda, include: diarrhea; vomiting; nausea; pain, redness, swelling, or sores in the mouth; pain, swelling, or redness of hands or feet that prevents normal activity; and fever or infection. It was also noted that it might interact with the blood-thinner warfarin and increase bleeding risk.
For more information about colorectal and breast cancer contact the National Cancer Institute at 800-4-Cancer, or visit them on line at http://www.cancer.gov/